MDR and IVDR Evidence Requirements in Transition
MedTech Leading Voice | Issue 189
📝 From the Editor
Deadlines ran through this week’s posts. Beat Keller reminded MDD certificate holders that the deadlines to stay in the MDR transition passed in 2024. Stefano Bolletta flagged 27 March 2027 as the latest recommended date for manufacturers to upload their own SS(C)Ps to EUDAMED. MDCG 2026-6 on orphan IVDs and ISO 20417:2026 were also published.
Last Friday, Maria E. Donawa, M.D. , walked 158 of us through how clinical data is appraised under the MDR. This Friday, Ethan Drower of CiteMed shows how to build the system that supports your claims.
— Sean Smith
🧠 Featured Post
Your MDD Certificate Runs to 2028. Did You Meet the 2024 Deadlines That Keep It Valid?
Beat Keller starts from a familiar assumption: the MDD certificate is valid until 2028, so there is still time. The extended transition periods under Article 120 MDR, as amended by Regulation (EU) 2023/607, are conditional. Each condition had a 2024 deadline. Companies needed a formal application to a notified body by 26 May 2024, a written agreement signed by 26 September 2024, and a QMS upgraded for MDR risk management and post-market surveillance by 26 May 2024.
The 31 December 2027 deadline (Class III and implantable Class IIb) and the 31 December 2028 deadline (other Class IIb, Class IIa, Class Is/Im/Ir) apply only when all three conditions were met. The device must also still comply with the MDD, have no significant change in design or intended purpose, and present no unacceptable risk. If a legacy device misses any of these, Beat’s line is that “the dates on your certificate are decoration.”
📌 This Week’s Top Posts (In no special order)
- Manufacturers Will Upload Their Own SS(C)Ps in EUDAMED. MDCG 2026-4 Rev.1 Sets 27 March 2027, announced by Stefano Bolletta.
- The Most Expensive Time to Fix Your Device’s Intended Purpose Is Mid-Project, published by EU MDR Compliance.
- FDA’s Final Order on OTC Sleep Apnea Devices Asks Whether Users Will Read a Low-Risk Result Correctly, reviewed by Larbi Al Moutaa.
- A Failed Penetration Test Weeks Before Submission Is a Design Controls Breakdown, emphasized by Vidya Vasudeva Rao.
- Do Third Party Reviewers Still Have a Role in Mexico? Plus Costa Rica’s IVD Classification Rules, summarized by Miguel Angel Torres Tello.
- A Head of QA/RA Rewrote CAPA Procedures That Had Passed Countless Audits, outlined by Georg Digel.
- Performance, Clinical Performance or Clinical Benefit? Why Notified Bodies Keep Writing the Same Deficiencies, explained by Cesare Magri.
- Japan’s PMDA Sets AI Principles for the Tools Regulatory Teams Use, underscored by Dr. Tobias Klämpfl.
- Your MDD Certificate Runs to 2028. Did You Meet the 2024 Deadlines That Keep It Valid?, clarified by Beat Keller.
- Can’t Prove Your Clinical Trial Software Is Validated? EMA May Not Accept the Data, overviewed by Esther Fernández Irueste.
- MDCG 2026-6 Sets Out What Premarket Data Is Acceptable for Orphan IVDs, noted by Corey Jaseph.
- ISO 20417:2026 Replaces the 2021 Edition and Introduces an “Applicable Policy”, highlighted by Stefano Bolletta.
🎯 Featured Event
Architecting a Claims Support System
Friday, November 13, 2026, 11:00 AM ET — How evidence leaders answer the EU, the FDA and their payers without starting over. This Friday In-Focus features Ethan Drower, Co-Founder and CEO of CiteMed.
Last week, Maria E. Donawa, M.D., showed that claims on your label, IFU, website or sales materials may have to come down if your clinical data doesn’t support them. Ethan’s session covers how to build the system that supports those claims.
🗓️ Upcoming Events & Webinars
- November 19, 2026 | 11:00 AM ET — Patient Personas: Information or Abomination?, featuring Merrill Zavod (Associate Director, ClariMed). Register Now >>
- November 20, 2026 | 11:00 AM ET — The Business Case for Quality, Part 2, featuring Michelle Lott, RAC (Principal and Founder, leanRAQA) and Tianna Benson (Senior Regulatory and Quality Manager, leanRAQA). Register Now >>
🎟️ Upcoming Conferences
- November 10–11 | Philadelphia, PA — PhMTI 2026 Fall Seminar: Human + Machine, The Enduring Value of Information Professionals in the Age of AI, at the Sofitel Philadelphia at Rittenhouse Square. Member rate $200. Register Now >>
💥 Weekly 510(k) Roundup
November 2, 2026 | From Marcus Engineering, LLC
71 clearances this week, including 28 first-time clearances (🚀). Featured clearances:
- 🚀 Evident Vascular, Inc. — Evident Vascular™ Guidance System: a tiny probe sends out high-frequency sound waves and uses the echoes to image the inside of blood vessels. It shows plaque buildup and narrowing along vessel walls, which helps doctors choose and place the right stent and confirm blood flow.
- 🚀 Bloom Surgical — SWICS™: a miniature wiper and fluid rinse clean the surgical camera lens while the camera stays inside the patient, so surgeons keep a clear view without pulling it out for cleaning.
- LymphaTech — LymphaTech Mobile 3D Measuring Tool: an infrared camera and an iPad build an accurate 3D model of a patient’s arm or leg without touching it. This makes it easier to track swelling from lymphedema after cancer treatment.
📋 Regulatory Roundup
Monday, 2 November 2026 | By Martin King
This edition argues that regulatory intelligence has to turn into regulatory action. NMPA, SAHPRA, Swissmedic and ANVISA show compliance moving from guidance to implementation. Swissmedic, the Egyptian Drug Authority, FDA, EMA and Health Canada are making submission quality and structured regulatory data strategic priorities. EMA, ENISA, the European Data Protection Board and Hong Kong’s Department of Health are looking harder at digital systems, cybersecurity and data protection.
PIC/S, Swissmedic and FDA treat lifecycle quality management as a continuing responsibility. FDA and EMA are tying clinical evidence more closely to scientific innovation. MHRA, MedTech Europe and EMA show market access and regulatory cooperation becoming more connected. EMA, Health Canada, ANVISA, PIC/S and Swissmedic are advancing international harmonisation, though local requirements remain. Across global authorities, oversight has to connect the entire product lifecycle. This week’s edition is also available as a flipbook.
🎤 In Case You Missed It
Methodological Quality and Scientific Validity Under the MDR
Last Friday, more than 296 people registered, and 158 joined live from 34 countries for an outstanding session with Maria E. Donawa, M.D., Founder and President of Donawa Lifescience. Her subject was how clinical study data is appraised under the MDR. Following MEDDEV 2.7/1 rev 4, each data set is judged first on methodological quality and scientific validity, then on relevance, and then weighted for its contribution to the clinical evaluation.
In the live poll, 19 of 26 respondents said they were somewhat familiar with clinical data appraisal or new to it. Maria advised teams to bring clinical evaluation expertise into design and development, and to learn the appraisal criteria before writing the clinical investigation plan.
🔥 Postscript
Don’t Be Overlooked
When a buyer asks AI for three names in your specialty, are you one of them? Get a free AI visibility audit, reviewed by me and in your inbox in 24 to 48 hours.
Message me to get your audit >>
Sean 🐝